Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry
Rapid Communications in Mass Spectrometry · 2025
DOI: 10.1002/rcm.10137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Chengzhen Guan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Bibenzyls. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Rationale
Chrysotoxine, a bibenzyl derivative from the stems of Dendrobium medicinal herbs, has recently emerged as a promising therapeutic candidate for cervical cancer. This study aimed to characterize chrysotoxine metabolites across multiple hepatocyte species and in rat urine.
Methods
Metabolites were identified and characterized using liquid chromatography coupled with benchtop Orbitrap high‐resolution mass spectrometry (LC–Orbitrap–MS/MS) combined with Compound Discoverer software. Structural elucidation relied on accurate mass measurements (mass error < 5 ppm) and comprehensive MS 2 fragmentation pattern interpretation.
Results
Twelve distinct metabolites were structurally identified. Among these, M4, M6, M7, M8, M10, M11, and M12 are newly reported. Metabolic transformations occurred via five principal pathways: hydroxylation, demethylation, glucuronidation, sulfation, and glutathione (GSH) conjugation. Cross‐species analysis of hepatocytes revealed direct glucuronidation as the predominant metabolic reaction. Urinary excretion profiles in rats identified hydroxylated (M9) and glucuronidated (M11) metabolites as the major elimination products. During the metabolism, chrysotoxine can be metabolized into quinone methide and ortho quinone intermediates that can be conjugated with GSH, forming the adducts M1, M2, M3, and M5.
Conclusions
This study delineates chrysotoxine metabolites in vitro and in vivo, providing critical insights for further pharmacokinetic and toxicity assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- The Health Policy Research Institute of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Meiling Wan
Zitieren
APA
Guan, C., An, Y., & Wan, M. (2025). Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10137
Vancouver
Guan C, An Y, Wan M. Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10137
BibTeX
@article{Guan2025,
author = {Guan, Chengzhen and An, Yiqiang and Wan, Meiling},
title = {Identification of the In Vitro and In Vivo Metabolites of Chrysotoxine Using Liquid Chromatography Combined With Benchtop Orbitrap High‐Resolution Mass Spectrometry},
journal = {Rapid Communications in Mass Spectrometry},
year = {2025},
doi = {10.1002/rcm.10137}
}
EUVIMED